MEMohamed I. Elsaid

Mohamed I. Elsaid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohamed I. Elsaid has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polygenic Risk Scores for Pancreatic Cancer Risk Prediction and Early Detection: A Systematic Evidence Review of Clinical Utility

    by Mohamed I. Elsaid, Yesung Kweon, Oindrila Bhattacharyya, Yousef Alish, Dongjun Chung, Soledad Fernández, Fode Tounkara, Asrar Alahmadi, Ashish Manne, Electra D. Paskett

    Background/Objectives: Pancreatic cancer carries a five-year relative survival of 13%. Polygenic risk scores (PRS) rank inherited susceptibility across common variants. Prior syntheses pooled PRS association and discrimination, but none asked whether a PRS changes a clinical decision. We synthesized evidence on the clinical utility of PRS for pancreatic cancer risk assessment. Methods: In this PROSPERO-registered review (CRD42024511326), we searched four databases through May 11, 2026, for studies evaluating a PRS for primary pancreatic cancer risk in adults, alone or with clinical predictors. We recorded discrimination as the prerequisite for utility and organized utility across five prespecified domains: threshold-based accuracy, incremental value, calibrated absolute risk, decision-analytic output, and economic impact. We synthesized narratively and appraised risk of bias with PROBAST. Results: Forty-three studies met the inclusion and exclusion criteria, including 25 from the UK Biobank. Ten of 16 standalone discrimination estimates fell between 0.56 and 0.64. Adding PRS to a clinical model increased discrimination by at most 0.05 in general populations. Combined PRS and clinical models exceeded 0.80 only in three diabetes-focused studies. Six studies reported calibration, four reclassification, two decision-curve net benefit, none cost-effectiveness, and 20 had no translational milestone. Thirteen studies were at high risk of bias, with 11 in the analysis domain. Conclusions: Pancreatic cancer PRS discriminates modestly alone and adds most where prior risk is highest. Actionable use awaits an externally validated absolute-risk model with a prespecified threshold and a decision analysis.

  • Open Access

    Nonlinear Association Between Metabolic Syndrome Severity and Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease

    by Mohamed I. Elsaid, Yesung Kweon, Na Li, Soledad Fernández, Electra D. Paskett, Khalid Mumtaz, Vinod K. Rustgi

  • Immune thrombocytopenia in patients treated with immune checkpoint inhibitors

    by Rebecca K. Leaf, Jodi V. Mones, Tushar Shenoy, Mohamed Warsame, Marina Beltrami-Moreira, Sandhya Panch, Andrew D. Leavitt, Rebecca L. Zon, Ellen K. Kendall, Sahar Shahamatdar, et al.

    Immune checkpoint inhibitor–associated immune thrombocytopenia (ICI-ITP) has been described in case reports and small case series, but comprehensive data on its incidence, risk factors, clinical features, treatment, and outcomes are lacking. We reviewed medical records of all adults initiating ICI therapy between 2016 and 2023 at 29 US hospitals across 7 major cancer centers to identify patients with ICI-ITP. Multivariable logistic regression was used to identify risk factors, and Cox modeling was performed to assess the association between ICI-ITP, its severity, and mortality. Among 86 467 patients, ICI-ITP occurred in 214 (0.25%). Independent risk factors included lower baseline platelet count, combination ICI therapy, stage IV cancer, and additional immune-related adverse events. ICI-ITP occurred at a median of 8 weeks (interquartile range [IQR], 4-18) after ICI initiation, with a median nadir platelet count of 41 × 109/L (IQR, 17 × 109/L to 64 × 109/L). Patients were treated with glucocorticoids (n = 106 [49.5%]), immune globulin (n = 39 [18.2%]), and thrombopoietin receptor agonists (n = 29 [13.6%]). Recovery occurred in 161 patients (75.2%) at a median of 2.3 weeks (IQR, 1.0-5.3). Of 76 patients rechallenged with ICIs, 23 (30.3%) developed recurrent ICI-ITP. ICI-ITP and its severity were associated with higher all-cause mortality, with a nearly threefold increase in risk among patients with severe ICI-ITP than those without ICI-ITP (adjusted hazard ratio, 2.96 [95% confidence interval, 2.14-4.08]). These findings establish ICI-ITP as a rare but clinically significant complication of ICI therapy, provide, to our knowledge, the first large-scale description of its risk factors and clinical course, and underscore the importance of timely recognition and management.


  • Open Access

    Impacts of Neighborhood Persistent Poverty and Socioeconomic Status on Hepatocellular Carcinoma Outcomes: A Large Population‐Based Cohort Study

    by Mohamed I. Elsaid, Holli A. Loomans‐Kropp, Yesung Kweon, Vinod K. Rustgi, Cecilia Dapino, Jesse J. Plascak, Samilia Obeng‐Gyasi, Chyke Doubeni, Na Li, Khalid Mumtaz, et al.

    Background: Hepatocellular carcinoma (HCC) survival in the United States varies sharply by neighborhood disadvantage. Aim: To determine whether residence in persistently impoverished or low‐SES census tracts is independently associated with lower all‐cause and HCC‐specific survival. Methods: We identified 51,323 adults with HCC using a population‐based retrospective cohort from the Surveillance, Epidemiology, and End Results Research Plus Specialized Database (2006–2020). Two census tract‐level socioeconomic exposures were defined: persistent poverty (≥ 20% living below the poverty line for approximately 30 years) and low SES (Yost Index first quintile). Overlap Propensity Score Weighting, combined with marginal structural models, estimated the 1‐, 5‐, 10‐, and 15‐year risks of all‐cause and HCC‐specific mortality. Results: The median follow‐up was 16 months, 6058 (11.8%) lived in persistently impoverished tracts, and 9863 (19.5%) lived in low‐SES tracts. After weighting, residents of persistently impoverished areas had a 1‐year all‐cause mortality risk of 46.0% vs. 40.3% (RD, 5.6%; 95% CI, 4.4% to 6.9%; RR, 1.14; 95% CI, 1.11 to 1.17) and an HCC‐specific mortality risk of 33.3% vs. 28.6% (RD, 4.8%; 95% CI, 3.2% to 6.3%; RR, 1.17; 95% CI, 1.11 to 1.22). Living in low‐SES tracts raised 1‐year all‐cause mortality risk to 32.5% vs. 30.1% (RD, 4.8%; 95% CI, 3.6% to 6.0%; RR, 1.12; 95% CI, 1.09 to 1.15) and HCC‐specific mortality risk to 32.5% vs. 30.1% (RD, 2.5%; 95% CI, 1.4% to 3.5%; RR, 1.08; 95% CI, 1.05 to 1.12). Conclusions: Both persistent neighborhood poverty and contemporary low SES independently contribute to significant increases in mortality risk after HCC diagnosis.


  • Open Access

    Racial and Ethnic Disparities in Pharmacologic and Non‐Pharmacologic Pain Management Among Older Cancer Survivors

    by Oindrila Bhattacharyya, Mohamed I. Elsaid, Brittany E. Punches, Andy Ni, Ashley S. Felix, Macarius M. Donneyong

    Introduction: Pain is common among cancer survivors and often managed with medication; however, racial‐ethnic disparities persist in pain treatment. Given inadequate data on pharmacologic and non‐pharmacologic pain management among minoritized cancer survivors, we investigated these patterns using the SEER‐Medicare claims linked database. Methods: An incident cancer diagnosis cohort (≥ 66 years) was created from 2007 to 2016. The primary outcome was incidence of pain treatment (pharmacologic and non‐pharmacologic) within 90 days post‐diagnosis. Racial disparities were measured as adjusted incidence ratios for treatment using Poisson regression and adjusted differences in supply days and doses using linear regression, comparing non‐Hispanic Black (nHB), Hispanic‐Latino (LatinX), Asian/Pacific Islander (API), and Others to non‐Hispanic White (nHW). Models were adjusted for demographic and clinical variables. Results: Among 300,048 survivors—nHW (72.9%), nHB (9.6%), LatinX (8.8%), API (7.3%), Others (1.4%)—nHB (aIR = 0.96, 95% CI, 0.95–0.98), API (aIR = 0.96, 95% CI, 0.95–0.98) and Others (aIR = 0.91, 95% CI, 0.87–0.94) used less pain treatment overall than nHW. Opioids (80% of treatments) were less frequently utilized by males of the Other race‐ethnicity group (aIR = 0.75, 95% CI, 0.70–0.81), compared to nHW males. For non‐opioids, nHB males (aIR: 0.84, 95% CI, 0.79–0.88) were less likely to use these therapies as compared to nHW males. Non‐pharmacological treatments were less utilized by nHB (aIR = 0.65, 95% CI, 0.62–0.69) and LatinX survivors (aIR = 0.69, 95% CI, 0.65–0.73), as compared to nHWs. Minority survivors received lower opioid doses for longer durations, but higher non‐opioid doses for shorter durations. Conclusion: There are considerable racial‐ethnic disparities in the utilization of pharmacologic and non‐pharmacologic pain treatments among cancer survivors. Future research should explore the drivers of these inequities.

  • Open Access

    Supplementary Figure 3 from Neighborhood Contexts and Healthcare Utilization in Patients with Breast Cancer Receiving Chemotherapy

    by Samilia Obeng-Gyasi, Demond Handley, Jesse J. Plascak, Jesus D. Anampa, J.C. Chen, Mohamed I. Elsaid

    Supplementary Figure 3 from Neighborhood Contexts and Healthcare Utilization in Patients with Breast Cancer Receiving Chemotherapy

  • Open Access

    Supplementary Table 5 from Neighborhood Contexts and Healthcare Utilization in Patients with Breast Cancer Receiving Chemotherapy

    by Samilia Obeng-Gyasi, Demond Handley, Jesse J. Plascak, Jesus D. Anampa, J.C. Chen, Mohamed I. Elsaid

    Supplemental Table 5 evaluates a dose response of healthcare utilization characterized by racial and economic residential segregation percentiles

  • Open Access

    Supplementary Figure 1 from Neighborhood Contexts and Healthcare Utilization in Patients with Breast Cancer Receiving Chemotherapy

    by Samilia Obeng-Gyasi, Demond Handley, Jesse J. Plascak, Jesus D. Anampa, J.C. Chen, Mohamed I. Elsaid

    Supplementary Figure 1 from Neighborhood Contexts and Healthcare Utilization in Patients with Breast Cancer Receiving Chemotherapy

  • Open Access

    Supplementary Table 11 from Neighborhood Contexts and Healthcare Utilization in Patients with Breast Cancer Receiving Chemotherapy

    by Samilia Obeng-Gyasi, Demond Handley, Jesse J. Plascak, Jesus D. Anampa, J.C. Chen, Mohamed I. Elsaid

    Supplementary Table 11 shows a preliminary causal mediation analysis examining the association between ICE-race-income and healthcare utilization

  • Open Access

    Supplementary Figure 2 from Neighborhood Contexts and Healthcare Utilization in Patients with Breast Cancer Receiving Chemotherapy

    by Samilia Obeng-Gyasi, Demond Handley, Jesse J. Plascak, Jesus D. Anampa, J.C. Chen, Mohamed I. Elsaid

    Supplementary Figure 2 from Neighborhood Contexts and Healthcare Utilization in Patients with Breast Cancer Receiving Chemotherapy